The builders of Russia’s Sputnik V vaccine for Covid-19 introduced on Tuesday that the two-dose vaccine will cost about $20 in international markets and wouldn’t require excessive chilly storage for distribution.
The cost of 1 dose of Sputnik V in international markets will probably be less than $10.
“Sputnik V is a two-dose vaccine. Therefore, Sputnik V will be two or more times cheaper than mRNA vaccines with similar efficacy levels,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) that has invested in manufacturing and promotion of the vaccine, advised a digital information convention.
“We are ready to start delivery of Sputnik V to foreign markets, thanks to partnerships with manufacturers in India, Brazil, South Korea, China and four other countries,” he added.
In India, RDIF has tied up with Dr Reddy’s Laboratories to produce the vaccine. Currently, part II and III trials are underway in India. Phase III trials are accepted and ongoing in Belarus, the UAE and Venezuela, RDIF mentioned.
Dmitriev mentioned RDIF and its companions have launched manufacturing of the lyophilised or dry type of the vaccine, which might be saved at a temperature of two to eight levels Celsius.
“Such a regime enables the distribution of the vaccine in international markets, as well as expanding its use in hard-to-reach regions, including areas with tropical climates,” RDIF mentioned in an announcement. Dmitriev mentioned this issue will make the distribution of Sputnik V cheaper.
RDIF, one of many world’s main sovereign funds, is increasing current agreements with international manufacturing companions to produce the vaccine for extra than 500 million folks a 12 months from 2021, the assertion mentioned.
RDIF can be contemplating further functions from a number of international locations and firms to enhance manufacturing capability. “The first international deliveries of the Russian Sputnik V vaccine will be made to customers in January 2021 based on the existing partnerships with foreign manufacturers,” the assertion mentioned. Customers who just lately submitted requests will obtain the primary batches of vaccine from March 2021.
RDIF additionally mentioned the “second interim analysis of clinical trial data showed a 91.4% efficacy for the Sputnik V vaccine on day 28 after the first dose”, whereas “vaccine efficacy is over 95% 42 days after the first dose”.
Currently, 40,000 volunteers are collaborating in part III double-blind, randomised, placebo-controlled medical post-registration examine of the Sputnik V vaccine in Russia, of whom extra than 22,000 volunteers have been vaccinated with the primary dose and extra than 19,000 volunteers with the primary and second doses.
“There were no unexpected adverse events during the trials. Monitoring of the participants is ongoing,” the assertion mentioned.
Sputnik V relies on the human adenoviral vector platform that RDIF mentioned had proved “safe and effective with no long-term side effects in more than 250 clinical trials” performed globally over the previous twenty years.
On August 11, Sputnik V was registered by Russia’s well being ministry and have become the world’s first registered vaccine in opposition to Covid-19.